MT Newswires
Baird Downgrades ResMed to Neutral From Outperform, Adjusts Price Target to $275 From $300
📊
AI Sentiment
Positive
7/10
ResMed Inc. News
Latest updates and market news for RMD
2 news
Dec 11 - Dec 17, 2025
Page 1
Share this news page